Your browser is no longer supported. Please, upgrade your browser.
Settings
APVO [NASD]
Aptevo Therapeutics Inc.
Index- P/E- EPS (ttm)-7.52 Insider Own5.82% Shs Outstand4.54M Perf Week1.31%
Market Cap83.89M Forward P/E- EPS next Y-5.18 Insider Trans0.00% Shs Float2.16M Perf Month-0.53%
Income-29.90M PEG- EPS next Q-1.48 Inst Own60.80% Short Float3.44% Perf Quarter-27.51%
Sales9.40M P/S8.92 EPS this Y38.20% Inst Trans-0.73% Short Ratio1.15 Perf Half Y-43.77%
Book/sh3.06 P/B5.57 EPS next Y8.50% ROA-50.20% Target Price- Perf Year123.17%
Cash/sh12.28 P/C1.39 EPS next 5Y- ROE-268.90% 52W Range6.17 - 60.00 Perf YTD-53.48%
Dividend- P/FCF- EPS past 5Y26.00% ROI- 52W High-71.58% Beta7.04
Dividend %- Quick Ratio- Sales past 5Y-33.70% Gross Margin- 52W Low176.34% ATR1.02
Employees58 Current Ratio2.10 Sales Q/Q520.00% Oper. Margin- RSI (14)45.46 Volatility4.27% 5.52%
OptionableNo Debt/Eq1.08 EPS Q/Q15.50% Profit Margin- Rel Volume0.73 Prev Close16.67
ShortableYes LT Debt/Eq0.31 Earnings- Payout- Avg Volume64.48K Price17.05
Recom2.00 SMA20-2.33% SMA50-6.07% SMA200-38.34% Volume47,191 Change2.28%
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Aug-17-21 08:05AM  
Aug-12-21 08:05AM  
Jul-16-21 08:05AM  
Jun-29-21 08:05AM  
May-27-21 09:00AM  
May-26-21 09:32AM  
09:00AM  
May-17-21 06:00AM  
May-11-21 09:00AM  
Apr-09-21 09:00AM  
Mar-31-21 08:00AM  
Feb-09-21 07:30PM  
Jan-11-21 08:00AM  
Jan-06-21 12:00PM  
Dec-19-20 01:45PM  
Dec-02-20 08:00AM  
Nov-20-20 07:37AM  
Nov-19-20 04:15PM  
Nov-16-20 08:00AM  
Nov-10-20 08:40AM  
Nov-09-20 09:00AM  
06:00AM  
Nov-08-20 11:15PM  
Nov-03-20 09:00AM  
Sep-01-20 09:00AM  
Aug-14-20 09:00AM  
Aug-06-20 09:00AM  
Jul-21-20 09:00AM  
Jun-30-20 12:00PM  
11:30AM  
Jun-29-20 09:00AM  
Jun-25-20 09:00AM  
Jun-10-20 09:00AM  
May-13-20 09:00AM  
Apr-14-20 09:00AM  
Mar-25-20 09:00AM  
Mar-16-20 09:00AM  
Feb-28-20 09:05AM  
08:59AM  
Jan-30-20 09:00AM  
Jan-13-20 08:00AM  
Dec-19-19 03:50PM  
Dec-06-19 09:00AM  
Nov-12-19 09:00AM  
Nov-08-19 09:00AM  
Nov-07-19 09:00AM  
Oct-04-19 07:32AM  
Oct-03-19 04:02PM  
04:02PM  
Sep-19-19 09:00AM  
Aug-09-19 09:00AM  
Aug-07-19 09:02AM  
Jul-25-19 04:32PM  
Jun-25-19 09:00AM  
May-09-19 09:00AM  
Apr-29-19 10:21AM  
Apr-26-19 08:31AM  
Apr-15-19 09:00AM  
Apr-11-19 12:26PM  
Apr-02-19 09:02AM  
Mar-25-19 09:02AM  
Mar-20-19 09:02AM  
Mar-18-19 09:00AM  
Mar-14-19 10:28AM  
Mar-07-19 09:13AM  
Mar-06-19 04:37PM  
Jan-07-19 08:30AM  
Jan-03-19 09:02AM  
Dec-21-18 09:00AM  
Dec-20-18 12:57PM  
Dec-13-18 09:02AM  
Dec-11-18 07:20AM  
Nov-20-18 09:00AM  
Nov-14-18 04:02PM  
Nov-09-18 12:00AM  
Oct-24-18 09:00AM  
Oct-10-18 08:40AM  
Sep-25-18 11:29AM  
Sep-05-18 11:36AM  
Aug-31-18 02:46PM  
Aug-09-18 09:00AM  
Aug-07-18 09:00AM  
Aug-06-18 08:10AM  
May-29-18 09:00AM  
May-15-18 07:40AM  
May-10-18 09:00AM  
May-08-18 09:02AM  
May-01-18 09:00AM  
Apr-30-18 07:50AM  
Apr-20-18 08:35PM  
Apr-16-18 09:02AM  
Mar-19-18 08:20AM  
Mar-13-18 09:02AM  
Mar-12-18 09:02AM  
Feb-27-18 09:02AM  
Jan-17-18 08:10AM  
Jan-11-18 09:04AM  
Jan-08-18 09:00AM  
Jan-03-18 08:17AM  
Dec-27-17 10:58AM  
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANG KEVIN C10% OwnerNov 06Buy22.73174,2773,961,8981,760,000Nov 06 04:47 PM
TANG KEVIN C10% OwnerNov 05Buy18.78625,72311,750,3071,585,723Nov 06 04:47 PM
TANG KEVIN C10% OwnerNov 04Buy14.35636,6759,137,026960,000Nov 06 04:47 PM